Back to results
US 11,897,969 B2Granted
Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
AssigneeThe Regents of the University of California
InventorsSotirios Tsimikas, Joseph L. Witztum, Xuchu Que
Life of this patent
Estimating the term…
Abstract
The disclosure provides for methods and treatments of ischemic injury, reperfusion injury, stroke and myocardial infarctions by administering within minutes to hours an antibody or antibody fragment that bind to and inhibits the biological activity of OxPL in an affected tissue.
Claims23
A method of reducing cardiomyocyte death associated with reperfusion-dependent oxidized phospholipid (OxPL) generation in a subject at risk thereof following a cardiac ischemic event, comprising
- administering a therapeutically effective amount of an antibody or antibody fragment that specifically binds to a phosphocholine headgroup of an oxidized phospholipid to the subject, wherein the antibody or antibody fragment comprises:
- a variable heavy chain domain (VH) that includes complementarity determining regions (CDRs) comprising amino acid sequences that are at least 95% identical to each of SEQ ID NO:6, 7, and 8;
- and a variable light chain domain (VL) that includes CDRs comprising amino acid sequences that are at least 95% identical to each of SEQ ID NO:9 or 12, 10, and 11, wherein the antibody or antibody fragment is administered within 10 hours after the ischemic event.
Dependencies are inferred from the claim text.